Citigroup
ORIC icon

Citigroup’s Oric Pharmaceuticals ORIC Stock Holding History

Citigroup’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,700
Closed -$703K – 6325
2021
Q1 		$703K Buy
+28,700
New +$907K ﹤0.01% 3225

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Citigroup's ORIC Position: Q1 2026 in Review

Citigroup reduced its Oric Pharmaceuticals (ORIC) stake by 89% in Q1 2026, selling an estimated $1.56M and leaving 16,994 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #3973.

Citigroup first reported a position in ORIC in Q2 2020 and has held it in 23 quarters since. The position peaked at $2.17M in Q1 2021. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Citigroup held 16,994 shares of Oric Pharmaceuticals worth $215K as of Q1 2026.
  • Citigroup sold 137,155 Oric Pharmaceuticals shares in Q1 2026, an estimated $1.56M.
  • Oric Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3973 holding.
  • Citigroup first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • Citigroup's Oric Pharmaceuticals position peaked at $2.17M in Q1 2021.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.